Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
Giampietro Gasparini(Fondazione IRCCS Istituto Nazionale dei Tumori), Dino Amadori(Ospedale G.B. Morgagni - L.Pierantoni), Gianfranco Filippelli(Presidio Ospedaliero), Matelda Zancan(Agenzia Regionale per la Protezione Ambientale del Piemonte), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Cognetti(Apple (Israel)), Diana Crivellari(Centro di Riferimento Oncologico), Francesco Torino(University of Rome Tor Vergata), A. Lambiase(Roche (Italy)), Paola Papaldo(Cancer Institute (WIA)), Luigi Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), Vittorio Silingardi(University of Modena and Reggio Emilia), Antonio Caputo(Presidio Ospedaliero), Massimo Gion(Agenzia Regionale per la Protezione Ambientale del Piemonte), A. Spada(Centro di Riferimento Oncologico), Livia De Sio(Ospedale San Filippo Neri)
Cited by 140
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751